Liver cancer combo shows promise for tumor shrinkage before surgery
NCT ID NCT05099848
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tested a combination of chemotherapy infused into the liver artery, plus two immunotherapy drugs (camrelizumab and apatinib) in 21 people with liver cancer that could not be removed by surgery. The goal was to shrink the tumors enough to allow complete surgical removal. The study looked at how many patients could then have successful surgery and how well the tumors responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shandong Cancer Hospital and Institute
Jinan, Shandong, 250117, China
Conditions
Explore the condition pages connected to this study.